synachten depot 1 mg/ml
mallinckrodt specialty pharmaceuticals ireland ltd - irlanda - tetracosactidum - susp. inj. - 1mg/ml - hormoni ai lobului hipofizar anterior si analogi acth
vistabel, 4 unitati allergan/0,1 ml
allergan pharmaceuticals ireland ltd. - irlanda - toxina botulinica de tip a unui - pulb. pt. sol. inj. - 4 unitati allergan/0,1ml - miorelaxante periferice alte miorelaxante cu actiune periferica
urorec capsule 4 mg
recordati ireland ltd - silodosinum - capsule - 4 mg
urorec capsule 8 mg
recordati ireland ltd - silodosinum - capsule - 8 mg
combigan 2 mg/ml + 5 mg/ml
allergan pharmaceuticals ireland - irlanda - combinatii (brimonidinum+timololum) - pic. oft., sol. - 2mg/ml+5mg/ml - antiglaucomatoase si miotice agenti betablocanti
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - clopidogrel clorhidrat - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenți antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
emtricitabina/tenofovir disoproxil accordpharma 200 mg/245 mg
pharmadox healthcare ltd - malta - combinatii (emtricitabinum+tenofovirum) - compr. film. - 200mg/245mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii
octagam
octapharma (ip) ltd. - imunoglobulina normala pt. adm. intravasculara - sol. perf. - 50mg/ml - imunoglobuline imunoglobulina umana normala
sitagliptin/clorhidrat de metformin pharmazac 50 mg/1000 mg
remedica ltd. - cipru - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/1000mg - analogi ai glp-1 combinatii de antidiabetice orale
sitagliptin/clorhidrat de metformin pharmazac 50 mg/850 mg
remedica ltd. - cipru - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/850mg - analogi ai glp-1 combinatii de antidiabetice orale